BPC-157 vs TB-500. The honest recovery peptide comparison.

Quick comparison at a glance

The short version — here is how BPC-157 and TB-500 (Thymosin Beta-4 Fragment) stack up on the questions most patients ask before picking one.

BPC-157

• Drug class: Synthetic pentadecapeptide
• Brand names: (compounded research peptide)
• Mechanism: Derived from a protein found in gastric juice. Animal studies suggest effects on wound healing, angiogenesis (blood vessel formation), and gut lining repair. Human clinical trial data is limited.
• Dosing: Research dosing has used subcutaneous injection, typically in the range of 250-500 mcg daily, though protocols vary widely. There is no FDA-approved dosing regimen.
• Half-life: Reported to be relatively short (minutes to hours) for systemic administration; local tissue effects may persist longer.
• FDA indication: None — BPC-157 is not FDA-approved for any indication.
• FDA status: NOT FDA-approved. Available through licensed compounding pharmacies under a valid prescription when clinically appropriate.
• Manufacturer: Licensed compounding pharmacies (not a brand manufacturer).
• Common side effects: Because BPC-157 has not been through formal human clinical trials, the full side effect profile is not well characterized. Reported concerns include injection site reactions and unknown long-term effects.
• Typical price range: Compounded BPC-157 programs typically run $150-$300/month depending on the pharmacy, dose, and duration.

TB-500 (Thymosin Beta-4 Fragment)

• Drug class: Synthetic peptide fragment of thymosin beta-4
• Brand names: (compounded research peptide)
• Mechanism: Fragment of a naturally occurring peptide involved in actin sequestration, cell migration, and angiogenesis. Animal studies suggest roles in wound healing and tissue repair.
• Dosing: Research dosing has typically used subcutaneous or intramuscular injection, with protocols varying widely. No FDA-approved dosing exists.
• Half-life: Reported to be longer than BPC-157 — protocols often involve less frequent dosing.
• FDA indication: None — TB-500 is not FDA-approved for any indication.
• FDA status: NOT FDA-approved. Available through licensed compounding pharmacies under a valid prescription when clinically appropriate.
• Manufacturer: Licensed compounding pharmacies.
• Common side effects: Not well characterized in humans. Reported concerns include injection site reactions and unknown long-term effects. Theoretical concerns about cell proliferation mechanisms in patients with cancer history exist but are not well studied.
• Typical price range: Typically similar to BPC-157 when compounded — $150-$300/month depending on pharmacy and dose.

The evidence picture — be honest

Any honest comparison of BPC-157 and TB-500 has to start with the evidence picture: neither peptide has gone through formal Phase 3 clinical trials in humans. The majority of what we know comes from preclinical animal studies — mostly rats and mice — published in smaller research journals.

Animal studies for BPC-157 have reported effects on gastric ulcer healing, tendon-to-bone healing, nerve regeneration, and anti-inflammatory responses. Animal studies for TB-500 have reported effects on wound healing, cardiac repair after injury, and angiogenesis. This preclinical signal is why these peptides are interesting to researchers and physicians.

Different mechanisms, sometimes stacked

The reason BPC-157 and TB-500 are sometimes stacked rather than compared head-to-head is that they appear to work on different aspects of tissue repair:

• BPC-157 animal studies suggest effects at the site of injury — gut lining, tendon-bone junction, wound edge. It is thought to promote local angiogenesis and modulate inflammatory signaling.
• TB-500 is derived from a peptide involved in cell migration. Animal studies suggest broader effects on cell movement and tissue remodeling, potentially useful for systemic recovery contexts.

Combining them in a stack is not based on human clinical trial data — it is based on a mechanistic theory that local wound signaling (BPC-157) and systemic cell migration (TB-500) would complement each other. Whether the theory holds up in practice for any specific patient is unknown.

Important compliance notes

Both BPC-157 and TB-500 are compounded research peptides. Neither is FDA-approved. Neither has been independently evaluated by the FDA for safety, efficacy, or manufacturing quality. The FDA has issued warnings about compounded peptides made from illicit or uncharacterized API sources.

Puri works with state-licensed compounding pharmacies that meet our sourcing and quality control requirements. If you are considering any compounded peptide through any telehealth platform, ask where the API comes from, what third-party testing is performed, and what the pharmacy's inspection history looks like. A responsible provider answers these questions directly.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

BPC-157

BPC-157 is sometimes prescribed off-label by physicians who focus on regenerative medicine or sports recovery for patients with tendon, ligament, or soft tissue injuries who have exhausted more established options. It is NOT a first-line treatment for any condition. A licensed physician weighs the limited evidence against the patient's clinical situation and goals before prescribing.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is sometimes prescribed off-label by physicians focused on regenerative medicine for patients with systemic soft tissue recovery needs. It is often discussed as a stack with BPC-157 under the theory that the two work on complementary mechanisms. A licensed physician makes the clinical decision and should be honest about the limited human evidence.